AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
India presents one of the world’s largest untapped opportunities for neurovascular screening
AGA affects up to 80 per cent of men across their lifetime and remains one of the most common and most psychologically challenging forms of hair loss
Subscribe To Our Newsletter & Stay Updated